Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Mirtazapine MAOIs

MAOIs MIRTAZAPINE Risk of severe hypertensive reactions and of serotonin syndrome > For signs and symptoms of serotonin toxicity, see Clinical Features of Some Adverse Drug Interactions, Serotonin toxicity and serotonin syndrome Additive inhibition of both serotonin and norepinephrine reuptake Avoid co-administration. MAOIs should not be started for at least 2 weeks after stopping mirtazapine (moclobemide can be started at least 1 week after stopping mirtazapine). Conversely, mirtazapine should not be started for at least 2 weeks after stopping MAOIs... [Pg.161]

The clinician should bear in mind the toxic potential for the various antidepressant medications when patients already have or develop suicidality. The TCAs and MAOIs have narrow therapeutic indices, whereas the SSRIs, SNRIs, nefa-zodone, and mirtazapine have wide therapeutic indices.22... [Pg.582]

Many commonly used medications also contain substances that are eliminated by the MAOIs and must not be taken by these patients. The list of medications to be avoided inclndes the narcotic pain reliever meperidine (Demerol), and many over-the-connter cold remedies containing dextromethorphan or pseudoephedrine. Finally, patients taking MAOIs must also avoid medications that elevate serotonin levels. This inclndes certain appetite snppressants and antidepressants including the SSRIs, venlafaxine, duloxetine, mirtazapine, nefazodone, and trazodone. Medications that interact with the MAOIs cannot be taken until at least 2 weeks after the MAOI has been stopped. [Pg.51]

Serotonin-Boosting Antidepressants. The SSRIs have also been studied in the treatment of generalized social anxiety disorder, and paroxetine, sertraline, and venlafaxine are effective. Preliminary data suggests that the serotonin-boosting atypical antidepressants (mirtazapine and nefazodone) may also be helpful. Like the MAOIs, they appear to be effective at doses comparable to those used to treat depression. They may help avoidant patients to gradually increase their social interaction and become more assertive. [Pg.334]

Serotonin-boosting antidepressants or longer-acting benzodiazepines are also both suitable first-line treatments for APD. For APD patients who are also troubled by depression, an antidepressant is obviously preferable. We also prefer to use antidepressants rather than benzodiazepines to treat APD patients who have a history of substance abuse. The current data suggests that any of the SSRls as well as nefazodone, mirtazapine, and venlafaxine may be helpful. When these do not work, a MAOI is a reasonable alternative provided the patient is willing to commit to the dietary regimen. [Pg.335]

Hypersensitivity to maprotiline or mirtazapine coadministration with monamine oxidase inhibitors (MAOIs). [Pg.1046]

Antidepressants MAOIs, TCAs, SSRIs, SNRIs, mirtazapine, venlafaxine Amphetamines, phentermine, methylphenidate, sibutramine... [Pg.357]

Mirtazapine does not significantly inhibit hepatic cytochrome P450 enzymes. Additive effects may occur when mirtazapine is combined with other drugs with sedative or vascular effects. Mirtazapine should not be used in combination with an MAOI or within 14 days of discontinuing treatment with an MAOI. When it is combined with fluvoxamine, a potent inhibitor of P450 enzymes— including 1A2, 2D6, and 3A4, which metabolizes mirtazapine—the plasma concentration of mirtazapine may be increased by up to fourfold (AnttUa et al. 2001 Demers et al. 2001). [Pg.41]

No data are available on the safety or efficacy of combining mirtazapine or nefazodone with MAOIs. Until studies are available, it is prudent to avoid such combinations. [Pg.143]

As previously noted, all currently available antidepressants enhance monoamine neurotransmission by one of several mechanisms. The most common mechanism is inhibition of the activity of SERT, NET, or both monoamine transporters (Table 30-2). Antidepressants that inhibit SERT, NET, or both include the SSRIs and SNRIs (by definition), and the TCAs. Another mechanism for increasing the availability of monoamines is inhibition of their enzymatic degradation (the MAOIs). Additional strategies for enhancing monoamine tone include binding presynaptic autoreceptors (mirtazapine) or specific postsynaptic receptors (5-HT antagonists and mirtazapine). Ultimately, the increased availability of monoamines for... [Pg.659]

Adverse drug reactions can result from combining MAO inhibitors wifh tricyclic/tetracyclic anfidepressanfs and related compounds, including carbamazepine, cyclobenzaprine, and mirtazapine, and should be avoided except by experts to treat difficult cases MAO inhibitors in combination with spinal anesthesia may cause combined hypotensive effects Combination of MAOIs and CNS depressants may enhance sedation and hypotension... [Pg.373]

An alternative categorisation of antidepressants is based solely on mechanism of action (Fig. 19.1). The majority of antidepressants, including TCAs, SSRIs and related compounds are reuptake inhibitors. Certain novel agents including trazodone and mirtazapine are receptor blockers while MAOIs are enzyme inhibitors. [Pg.368]

The novel compounds nefazodone and trazodone usually require titration to a minimum therapeutic dose of at least 200 mg/day. Response to reboxetine, venlafaxine and mirtazapine may occur at the starting dose but some dose titration is commonly required. Venlafaxine is licensed for treatment-resistant depression by gradual titration from 75 to 375 mg/day. There is some need for dose titration when using MAOIs although recommended starting doses (e.g. phenelzine 15 mg t.d.s.) may be effective. Unlike other drug classes, reduction to a lower maintenance dose is recommended after a response is achieved. [Pg.373]

Mirtazapine MAOIs Theoretically central serotonin syndrome could occur... [Pg.1247]

DA agonists levodopa, bromocriptine, ropinirole, pramipexole, selegiline AAAD inhibitor carbidopa M-blockers benztropine, trihexiphenidyl MAOIs phenelzine, tranylcypromine TCAs amitriptyline, imipramine, clomipramine SSRIs fluoxetine, paroxetine, sertraline Others bupropion, mirtazapine, nefazodone, trazodone... [Pg.468]

The manufacturers siay that two weeks should elapse between taking an MAOI and mirtazapine. Mirtazapine combined with other serotonergic antidepressants may possibly increase the risk of bleeding and/or the serotonin syndrome. SSRIs may increase plasma levels of mirtazapine and there is a report of hypomania associated with combined use. The concurrent use of mirtazapine with amitriptyline may have a minor effect on the levels of both drugs. [Pg.1208]

No adverse interaetions have been reported between mirtazapine and the MAOIs but, to be on the safe side, the manufaeturers say that the eon-current use of mirtazapine and MAOIs should be avoided both during and within two weeks of stopping treatment. ... [Pg.1208]


See other pages where Mirtazapine MAOIs is mentioned: [Pg.575]    [Pg.272]    [Pg.298]    [Pg.236]    [Pg.4]    [Pg.273]    [Pg.301]    [Pg.668]    [Pg.272]    [Pg.250]    [Pg.274]    [Pg.677]    [Pg.374]    [Pg.183]    [Pg.1246]    [Pg.176]   
See also in sourсe #XX -- [ Pg.1208 ]




SEARCH



MAOI

Mirtazapine

© 2024 chempedia.info